At the Annual European Congress of Rheumatology (EULAR 2016) in London, Eli Lilly and Company (LLY) and Incyte (INCY) presented data from RA-BEYOND study, demonstrating that their drug baricitinib was superior to placebo at inhibiting progressive radiographic joint damage in patients with rheumatoid arthritis (RA).
A key goal of rheumatoid arthritis treatment is to impede the structural damage that this disease usually causes to the joints. Baricitinib has succeeded in curbing the damage. If approved this drug will offer an oral option that halts joint damage in a sustained effect that extends over . . .